Table 2. Treatment patterns in patients with stage III NSCLC.
| Treatment pattern | Total stage III NSCLC (N=1,838) | Stage IIIA NSCLC (n=1,082) | Stage IIIB NSCLC (n=756) |
|---|---|---|---|
| Surgery, n (%) | 484 (26.3) | 400 (37.0) | 84 (11.1) |
| (Bi)lobectomy or pneumonectomy | 344 (18.7) | 295 (27.3) | 49 (6.5) |
| Other and unspecified procedures | 88 (4.8) | 62 (5.7) | 26 (3.4) |
| Other and unspecified resection | 19 (1.0) | 14 (1.3) | 5 (0.7) |
| Other lung or tracheobronchial resection | 19 (1.0) | 16 (1.5) | 3 (0.4) |
| Thoraco-mediastinal resection | 0 | 0 | 0 |
| Missing | 14 (0.8) | 13 (1.2) | 1 (0.1) |
| Any radiotherapy, n (%) | 1,095 (59.6) | 609 (56.3) | 486 (64.3) |
| Planned neoadjuvant treatment, n (%) | 281 (15.3) | 216 (20.0) | 65 (8.6) |
| Planned neoadjuvant treatment and went on to receive surgery, n (%) | 138 (7.5) | 113 (10.4) | 25 (3.3) |
| Initial treatment received, n (%) | |||
| Neoadjuvant SACT then surgery | 133 (7.2) | 105 (9.7) | 28 (3.7) |
| Surgery with adjuvant SACT | 254 (13.8) | 211 (19.5) | 43 (5.7) |
| Surgery alone | 92 (5.0) | 80 (7.4) | 12 (1.6) |
| Sequential chemoradiotherapy | 193 (10.5) | 91 (8.4) | 102 (13.5) |
| Concurrent chemoradiotherapy | 607 (33.0) | 327 (30.2) | 280 (37.0) |
| SACT ± palliative radiotherapy | 373 (20.3) | 168 (15.5) | 205 (27.1) |
| Radiotherapy alone | 80 (4.4) | 45 (4.2) | 35 (4.6) |
| No treatment | 92 (5.0) | 45 (4.2) | 47 (6.2) |
| Other treatments† | 14 (0.8) | 10 (0.9) | 4 (0.5) |
| Time (days) from start of neoadjuvant SACT to surgery | |||
| n (%) | 124 (6.7) | 100 (9.2) | 24 (3.2) |
| Median (Q1–Q3) | 96.5 (82.0–118.0) | 98.5 (85.0–121.0) | 83.0 (68.0–111.0) |
| Completeness of resection, n (%) | |||
| R0 | 75 (60.5) | 62 (62.0) | 13 (54.2) |
| R1 | 7 (5.6) | 5 (5.0) | 2 (8.3) |
| R2 | 7 (5.6) | 5 (5.0) | 2 (8.3) |
| Missing | 35 (28.2) | 28 (28.0) | 7 (29.2) |
| Time (days) from start of surgery to adjuvant SACT | |||
| n (%) | 254 (13.8) | 211 (19.5) | 43 (5.7) |
| Median (Q1–Q3) | 43.5 (35.0–54.0) | 43.0 (35.0–54.0) | 46.0 (35.0–55.0) |
†, includes surgery with (neo)adjuvant radiotherapy, curative SACT with radiotherapy, concurrent chemoradiotherapy with immunotherapies, and other SACT with radiotherapy. NSCLC, non-small cell lung cancer; SACT, systemic anticancer therapy; Q, quartile.